Noile-Immune Biotech Inc
TSE:4893
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
124
312
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Noile-Immune Biotech Inc
Gross Profit
Noile-Immune Biotech Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
N
|
Noile-Immune Biotech Inc
TSE:4893
|
Gross Profit
ÂĄ314.6m
|
CAGR 3-Years
49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Gross Profit
ÂĄ17.9B
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
59%
|
||
PeptiDream Inc
TSE:4587
|
Gross Profit
ÂĄ35.5B
|
CAGR 3-Years
39%
|
CAGR 5-Years
46%
|
CAGR 10-Years
56%
|
||
Takara Bio Inc
TSE:4974
|
Gross Profit
ÂĄ26B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
||
Pharma Foods International Co Ltd
TSE:2929
|
Gross Profit
ÂĄ47.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
40%
|
CAGR 10-Years
49%
|
||
C
|
Cuorips Inc
TSE:4894
|
Gross Profit
ÂĄ9.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Noile-Immune Biotech Inc
Glance View
Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
See Also
What is Noile-Immune Biotech Inc's Gross Profit?
Gross Profit
314.6m
JPY
Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Gross Profit amounts to 314.6m JPY.
What is Noile-Immune Biotech Inc's Gross Profit growth rate?
Gross Profit CAGR 3Y
49%
Over the last year, the Gross Profit growth was -49%. The average annual Gross Profit growth rates for Noile-Immune Biotech Inc have been 49% over the past three years .